Leucid Bio

OverviewSuggest Edit

Leucid Bio is a biotech company providing cell therapies for patients with cancer. It develops CAR (chimeric antigen receptor) T (treatment)-cell therapy in which the patient's own immune cells are reprogrammed so they can recognise and destroy cancer cells.

Latest Updates

Employees (est.) (Dec 2021)9
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Leucid Bio Financials and Metrics

Summary Metrics

Founding Date


Leucid Bio total Funding

$15.9 m

Leucid Bio latest funding size

$15.88 m

Time since last funding

3 months ago

Leucid Bio investors

Leucid Bio's latest funding round in October 2021 was reported to be $15.9 m. In total, Leucid Bio has raised $15.9 m
Show all financial metrics

Leucid Bio Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Leucid Bio Online and Social Media Presence

Embed Graph

Leucid Bio News and Updates

Leucid Bio and Lonza Enter Strategic Collaboration to Leverage the Cocoon® Platform for Automated Manufacturing of Personalised CAR T-Cells

LONDON, Dec. 2, 2021 /PRNewswire/ -- Leucid Bio ("Leucid" or the "Company"), a biotech company pioneering next-generation cell therapies for hard-to-treat cancers, today announces that it has entered a strategic collaboration with Lonza to utilize Lonza's Cocoon® Platform for the...

Leucid Bio Raises £11.5M in Series A Funding

Leucid Bio, a London UK-based biotech company, raised £11.5M in series A funding

Leucid Bio Frequently Asked Questions

  • When was Leucid Bio founded?

    Leucid Bio was founded in 2014.

  • How many employees does Leucid Bio have?

    Leucid Bio has 9 employees.

  • Who are Leucid Bio competitors?

    Competitors of Leucid Bio include Nuvectis Pharma, Actym Therapeutics and PIC Therapeutics.